Group Gp Lp Column III Purchases 69,739 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating) major shareholder Group Gp Lp Column III purchased 69,739 shares of the firm’s stock in a transaction on Thursday, January 19th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $174,347.50. Following the purchase, the insider now directly owns 9,870,274 shares of the company’s stock, valued at $24,675,685. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

  • On Tuesday, January 17th, Group Gp Lp Column III purchased 49,463 shares of Tenaya Therapeutics stock. The shares were acquired at an average price of $2.49 per share, for a total transaction of $123,162.87.

Tenaya Therapeutics Stock Up 13.8 %

Tenaya Therapeutics stock opened at $3.22 on Wednesday. The stock has a 50-day simple moving average of $2.29 and a 200 day simple moving average of $3.33. Tenaya Therapeutics, Inc. has a 12-month low of $1.64 and a 12-month high of $16.17. The stock has a market capitalization of $133.23 million, a price-to-earnings ratio of -1.15 and a beta of 1.61.

Tenaya Therapeutics (NASDAQ:TNYAGet Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). As a group, sell-side analysts anticipate that Tenaya Therapeutics, Inc. will post -2.72 EPS for the current year.

Wall Street Analysts Forecast Growth

TNYA has been the subject of a number of analyst reports. Canaccord Genuity Group initiated coverage on Tenaya Therapeutics in a report on Tuesday, November 8th. They set a “buy” rating and a $21.00 price objective for the company. Canaccord Genuity Group initiated coverage on Tenaya Therapeutics in a report on Monday, November 7th. They set a “buy” rating for the company. Morgan Stanley cut their price objective on Tenaya Therapeutics from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Chardan Capital cut their price objective on Tenaya Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Friday, November 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $21.75.

Institutional Trading of Tenaya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank bought a new stake in Tenaya Therapeutics during the 1st quarter worth about $29,000. Bank of America Corp DE raised its holdings in Tenaya Therapeutics by 24.2% during the 1st quarter. Bank of America Corp DE now owns 18,305 shares of the company’s stock worth $216,000 after purchasing an additional 3,566 shares during the last quarter. California State Teachers Retirement System raised its holdings in Tenaya Therapeutics by 62.2% during the 1st quarter. California State Teachers Retirement System now owns 12,208 shares of the company’s stock worth $144,000 after purchasing an additional 4,682 shares during the last quarter. American International Group Inc. raised its holdings in Tenaya Therapeutics by 91.8% during the 1st quarter. American International Group Inc. now owns 14,195 shares of the company’s stock worth $167,000 after purchasing an additional 6,794 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Tenaya Therapeutics by 11.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 75,940 shares of the company’s stock worth $220,000 after purchasing an additional 7,541 shares during the last quarter.

About Tenaya Therapeutics

(Get Rating)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

Featured Articles

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.